Filing Flows › Insight Molecular Diagnostics (IMDX) › R&D spending
Insight Molecular Diagnostics (IMDX) R&D spending by quarter
Insight Molecular Diagnostics' R&D spending was $4.5M in Q2 2026 (second quarter 2026), -23% from Q4 2025. Over the last 6 quarters it ranged from $2.3M (Q4 2024) to $5.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.5M | -23% | +37% |
| Q4 2025 | $5.8M | +50% | +158% |
| Q3 2025 | $3.9M | +19% | — |
| Q2 2025 | $3.3M | +12% | — |
| Q1 2025 | $2.9M | +30% | — |
| Q4 2024 | $2.3M | — | — |
Q2 2026 at a glance
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Insight Molecular Diagnostics' R&D spending?
Insight Molecular Diagnostics' R&D spending was $4.5M in Q2 2026 (second quarter 2026), -23% from Q4 2025.
How has Insight Molecular Diagnostics' R&D spending changed?
Over the last 6 quarters it ranged from $2.3M (Q4 2024) to $5.8M (Q4 2025).
Q2 2026 results → · How Insight Molecular Diagnostics makes money →